E. Stevens
SUNY Downstate Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by E. Stevens.
Gynecologic Oncology | 2013
Camilla Guitarte; Ioannis Alagkiozidis; Benjamin Mize; E. Stevens; Ghadir Salame; Yi-Chun Lee
OBJECTIVE The purpose of this study is to summarize the data on the incidence, clinical behavior and overall survival of patients with glassy cell cervical carcinoma (GCCC). METHODS Twenty-four case series and fifteen case reports identified by searching PubMed database qualified for inclusion in this study. The published cases were combined with data from a retrospective chart review of patients with GCCC in two major teaching hospitals in Brooklyn, NY. RESULTS A total of 292 cases were collected through our literature and chart review. Median age at diagnosis was 45 years old (range 12-87 years of age). GCCC incidence ranges from 0.2 to 9.3% of all cervical cancers and 2 to 30.2% of cervical adenocarcinomas. The stage distribution is similar to squamous cell carcinoma with 79% of the patients being diagnosed with Stage I or II disease. Most common sites of recurrence for Stage I patients are the vagina and pelvis. In Stage II patients locoregional and distant metastases are equally common. Recurrence rate was higher among patients treated only with surgery (32.7%), as compared to patients treated with surgery followed by radiation (11%) or patients treated with radiation only (10%). Median overall survival (OS) was 25 months (95% CI 8.4-41.6). Overall 5-year survival for all stages is lower when compared to all cervical cancers (54.8% vs 75%). There was no interaction between race and OS (p=0.66). CONCLUSION GCCC is a rare histologic type of cervical cancer that presents at a younger age, is associated with high risk for distant failure and carries worse prognosis as compared to the squamous cell type. Radiation therapy is associated with decreased risk of recurrence.
Gynecologic Oncology | 2011
Tana S. Pradhan; E. Stevens; Michael Ablavsky; Ghadir Salame; Yi-Chun Lee; Ovadia Abulafia
OBJECTIVES The purpose of this study is to detect differences in overall survival between the 1988 FIGO staging and current staging of uterine carcinosarcomas to determine if revised 2009 staging accurately predicts actual patient survival. METHODS From 1988 until 2010, patients with uterine carcinosarcoma were retrospectively identified from tumor registry records. Patients were grouped in both broad stages (1-4) and all FIGO substages in order to detect differences. Time-dependent receiver operating characteristic curves (ROC) were generated to predict death before the end of the second year post-diagnosis for both the new and revised system. Kaplan Meier estimated median survival time was utilized to compare actual patient survival. RESULTS Of 112 patients with carcinosarcoma, 37 patients (33%) had FIGO Stage I disease, 15 patients (13.4%) had Stage II disease, 36 patients (32%) were diagnosed as Stage III, and 24 patients (21.4%) had Stage IV disease. 106 of 112 (94.6%) patients underwent lymphadenectomy (pelvic +/- para-aortic). Four patients (3.6%) were downstaged when utilizing broad staging criteria: 2 patients were downstaged from Stage II to I, and 2 patients were downstaged from Stage III to Stage I and II respectively. When looking at substage, the area under the ROC was 0.67 for the former staging system, and 0.65 for the revised staging. Kaplan-Meier estimated median survival time post-diagnosis was 610 days (95% CI [478,930]). CONCLUSION Based upon our reclassification of 112 patients with uterine carcinosarcoma, the revised FIGO staging system does not predict survival more accurately than former staging. Carcinosarcoma has an overall poor prognosis and better indicators of survival are needed.
American Journal of Hospice and Palliative Medicine | 2013
Lilly Singh; E. Stevens
Gynecologic malignancies affect more than 83 000 women in the United States, each year. Because the disease involves the pelvis, many patients have side effects distal to this area in their lower extremities. The differential diagnosis of leg pain can be divided into vascular, neurologic, and musculoskeletal causes. In this review article, we address numerous etiologies of leg pain, reviewing the prevalence of disease, physical examination findings, diagnostic as well as treatment modalities.
Gynecologic Oncology | 2013
E. Stevens; C. Gartman; Ehsan Sarafraz-Yazdi; Josef Michl
Gynecologic Oncology | 2013
E. Stevens; C. Pardo; Yi-Chun Lee; Ovadia Abulafia
Gynecologic Oncology | 2013
My-Linh T. Nguyen; C. LaFargue; M. Karsy; E. Stevens; S. McKernan; Tarah L. Pua; C. Gorelick; Sean S. Tedjarati; T.S. Pradhan
Gynecologic Oncology | 2013
E. Stevens; M. Henretta
Gynecologic Oncology | 2013
G. von Walstrom; E. Stevens; M. Fatehi; Ghadir Salame; Yi-Chun Lee; C. Gorelick; K. Economos
Gynecologic Oncology | 2012
E. Stevens; D. Leon; J. Blumberg; Tana S. Pradhan; Ghadir Salame; Ovadia Abulafia; Yi-Chun Lee
Gynecologic Oncology | 2012
E. Stevens; R. Rana; J. Jaffe; J. Blumberg; Tana S. Pradhan; Yi-Chun Lee